{"id":169160,"date":"2024-04-27T02:40:17","date_gmt":"2024-04-27T06:40:17","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/unity-biotechnology-announces-upcoming-presentations-at-the-arvo-2024-annual-meeting-globenewswire\/"},"modified":"2024-08-17T16:14:44","modified_gmt":"2024-08-17T20:14:44","slug":"unity-biotechnology-announces-upcoming-presentations-at-the-arvo-2024-annual-meeting-globenewswire","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/unity-biotechnology-announces-upcoming-presentations-at-the-arvo-2024-annual-meeting-globenewswire.php","title":{"rendered":"UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting &#8211; GlobeNewswire"},"content":{"rendered":"<p><p>    SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) --    UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a    biotechnology company developing therapeutics to slow, halt, or    reverse diseases of aging, today announced that the Company    will present two poster presentations at the Association for    Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting    being held on May 5-9, 2024 in Seattle, Washington.  <\/p>\n<p>    ARVO 2024 Presentation Details:  <\/p>\n<p>    Title: Effect of Patient Baseline    Characteristics on Response to UBX1325, a Novel Senolytic    Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks    follow-up    Posterboard Number: B0103    Date & Time: Monday, May 6, 2024 at 8:30     10:15 a.m. PDT    Location: Exhibit Hall - Seattle Convention    Center    Presenter: Dante Joseph Pieramici, M.D.,    California Retina Consultants  <\/p>\n<p>    Title: Senolytic drug candidate in wet AMD    demonstrates benefit with Multifocal ERG testing    Posterboard Number: B0391    Date & Time: Wednesday, May 8, 2024 at 2:15     4:00 p.m. PDT    Location: Exhibit Hall - Seattle Convention    Center    Presenter: Raj K. Maturi, M.D., Midwest Eye    Institute  <\/p>\n<p>    Additional presentation details and abstracts are available on    the ARVO 2024 website here.  <\/p>\n<p>    About UNITY    UNITY is developing a new class of therapeutics to slow, halt,    or reverse diseases of aging. UNITYs current focus is on    creating medicines to selectively eliminate or modulate    senescent cells and thereby provide transformative benefit    inage-relatedophthalmologic and neurologic    diseases. More information is available atwww.unitybiotechnology.comor    follow us onX    andLinkedIn.  <\/p>\n<p>    Media Contact    Inizio Evoke Comms    Katherine Smith    <a href=\"mailto:Katherine.Smith@inizioevoke.com\">Katherine.Smith@inizioevoke.com<\/a>  <\/p>\n<p>    Investor Contact    LifeSci Advisors, LLC    Joyce Allaire    <a href=\"mailto:jallaire@lifesciadvisors.com\">jallaire@lifesciadvisors.com<\/a>  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/04\/25\/2869604\/0\/en\/UNITY-Biotechnology-Announces-Upcoming-Presentations-at-the-ARVO-2024-Annual-Meeting.html\" title=\"UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting - GlobeNewswire\" rel=\"noopener\">UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting - GlobeNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/unity-biotechnology-announces-upcoming-presentations-at-the-arvo-2024-annual-meeting-globenewswire.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-169160","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169160"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169160"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169160\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}